CSPC Pharma stock falls 4.84 percent on October 8

Published on 10/08/2026 at 08:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CSPC Pharma stock's first-half revenue reached RMB 18,594 million, up 40.1 percent year over year. Reported profit rose 139.2 percent to RMB 6,094 million in 2026.

CSPC Pharma, HK1093012172, Illustration mit AI erstellt.

CSPC Pharma (ISIN HK1093012172) fell 4.84 percent on HKEX on October 8, 2026, extending the session's focus toward the company's valuation after a strong first-half earnings update. The stock was trading at HKD 9.34 in Hong Kong at 2:34 p.m. HKT, compared with a prior close of HKD 9.81.

Stock trades below yearly high

CSPC Pharma's intraday range ran from HKD 9.34 to HKD 10.04 on October 8, 2026. The share price was 14.8 percent below its 52-week high of HKD 10.96 and 43.0 percent above its 52-week low of HKD 6.53.

The company had a market capitalization of HKD 106.5 billion and trading volume of 61,241,880 shares at the quoted time. Those figures place the day's decline in a larger valuation picture rather than isolating it from the stock's recent trading range.

Interim profit rose 139.2 percent

According to CSPC Pharmaceutical Group, first-half 2026 revenue reached RMB 18,594 million, an increase of 40.1 percent from the prior-year period. Reported profit attributable to shareholders rose 139.2 percent to RMB 6,094 million, while underlying profit increased 165.8 percent to RMB 6,164 million.

The earnings mix also matters. Finished-drug revenue reached RMB 16,061 million, up 56.7 percent year over year, while licensing-fee income climbed 448.5 percent to RMB 5,895 million, according to FilingReader.

Consensus target remains higher

MarketScreener lists a consensus Buy rating from 24 analysts and an average price target of HKD 12.54. That target lies 34.3 percent above the HKD 9.34 trading price, giving the consensus a clear numerical gap to the market quotation.

As Futunn reported on October 5, 2026, CSPC will present eight clinical trial updates at the ESMO Congress in Madrid beginning October 23, 2026, including two late-breaking abstracts. The event gives investors a dated checkpoint for the oncology pipeline after the interim results highlighted licensing income and finished-drug growth.

CSPC Pharma stock trades at HKD 9.34

CSPC Pharma stock was trading at HKD 9.34 on HKEX on October 8, 2026, at 2:34 p.m. HKT. The next material company date is October 23, 2026, when the ESMO Congress begins.